Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2004
Business Overview: Eli Lilly operates primarily in the pharmaceutical products segment, with a minor animal health segment included in reporting. The company focuses on the development, manufacture, and marketing of pharmaceutical products for human and animal health.
Key Financial Metrics
Revenue and Profit (Six Months Ended June 30, 2004):
- Net Sales: $6,933.2 million (up 16% from $5,977.6 million in 2003).
- Net Income: $1,057.3 million (down 4% from $1,099.2 million in 2003).
- Earnings Per Share (Diluted): $0.97 (down from $1.02 in 2003).
- Gross Margin: 77.7% of net sales (down 1.1 percentage points from prior year).
Cash Flow and Liquidity:
- Cash and Cash Equivalents: $2,396.7 million (down from $2,756.3 million at year-end 2003).
- Short-term Investments: $1,014.8 million.
- Net Cash Provided by Operating Activities: $1,521.2 million.
- Net Cash Used in Investing Activities: $1,520.0 million (driven by $971.7 million in capital expenditures and acquisition costs).
- Net Cash Used in Financing Activities: $374.0 million (primarily dividends of $769.2 million).
Debt and Capital Structure:
- Total Debt: $5,129.7 million ($1,597.7 million short-term borrowings + $3,532.0 million long-term debt).
- Share Repurchases: No shares repurchased under the $3.0 billion program during the first half of 2004; $2.08 billion of the program had been utilized as of June 30, 2004.
Material Changes vs. Prior Period
Revenue Growth: Sales increased 15% in Q2 and 16% in the first half of 2004, driven by strong performance in Zyprexa, Strattera, Evista, Forteo, and Gemzar. International sales grew 20-22%, outpacing U.S. growth of 12%.
Expense Increases: Operating expenses rose significantly. Research and development (R&D) increased 26% in Q2 and 24% in the first half due to clinical trial costs. Marketing and administrative expenses increased 12-14% to support new product launches.
Special Charges:
- Q2 2004: Asset impairment charges of $108.9 million related to strategic manufacturing and R&D reviews.
- Q1 2004: Acquired in-process research and development (IPR&D) charge of $362.3 million related to the Applied Molecular Evolution (AME) acquisition.
Profitability Impact: Despite revenue growth, net income declined due to the aforementioned special charges and operating expenses growing faster than sales.
Guidance, Outlook, and Risks
2004 Financial Expectations:
- Earnings Per Share: Expected to be in the range of $2.39 to $2.44 for the full year, excluding future unusual items. This includes the impact of the $0.33 per share IPR&D charge and $0.08 per share asset impairment charge already incurred.
- Sales Growth: Low double-digit growth expected for the full year.
- Product Outlook: Continued strong international growth for Zyprexa; U.S. Zyprexa sales expected to decline in the second half compared to 2003. Gross margins expected to decline approximately 1.5 percentage points.
Key Risks and Contingencies:
- Patent Litigation (Zyprexa): Three generic manufacturers (Zenith, Reddy, Teva) have challenged U.S. patents. A trial court ruling is expected in summer 2004. An unfavorable outcome could materially adversely impact results.
- Patent Litigation (Evista): Barr Laboratories has challenged patents; trial scheduled for February 2006.
- Government Investigations: Ongoing civil and grand jury investigations regarding marketing and promotional practices for Evista, Prozac, and Zyprexa. Potential outcomes include fines and penalties.
- Product Liability: Numerous lawsuits involving Zyprexa (diabetes claims), DES, and thimerosal. Accruals of approximately $218.2 million have been recorded for litigation and environmental liabilities.
Investor Verification Checklist
- Patent Litigation Status: Monitor the summer 2004 ruling on Zyprexa patent challenges and potential generic entry.
- Government Investigations: Track developments in the DOJ and U.S. Attorney investigations regarding marketing practices for Zyprexa and Prozac.
- Product Launch Success: Verify sales performance of new launches (Cymbalta, Alimta, Symbyax) and the impact of the Evista launch in Japan.
- Debt Management: Confirm the refinancing of short-term borrowings and the redemption of $825 million in long-term debt scheduled for August 2004.
- Expense Trajectory: Assess whether R&D and marketing expense growth rates align with the projected mid-teens and single-digit growth for the full year.